Advertisement

Topics

MannKind Corporation Company Profile

00:23 EST 24th November 2017 | BioPortfolio

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA(TM) and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of AFREZZA for the treatment of adults with Type 1 or Type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response to this NDA from the FDA requesting additional information. An End-of-Review meeting was held in June 2010 and MannKind is currently preparing its resubmission of the AFREZZA NDA. Other products in MannKind's pipeline include the cancer immunotherapy products MKC1106-PP and MKC1106-MT, which are currently in phase 1 clinical trials. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.


News Articles [155 Associated News Articles listed on BioPortfolio]

MannKind moves headquarters within California

MannKind announced that it has relocated its headquarters from Ventura, Calif., to Westlake Village, Calif. MannKind also has a manufacturing facility in Danbury, Conn.

MannKind: Afrezza Scripts Rebound To Highest Level Yet Under MannKind Control

Mannkind nets $57.7mm via RDO

MannKind Corp., whose lead product is the diabetes therapy Afrezza, netted $57.7mm through the registered direct offering of 10.17mm common shares at $6 each (a 62% premium) to institutional investors...

Mannkind nets $58mm via RDO

MannKind Corp., whose lead product is the diabetes therapy Afrezza, netted $58mm through the registered direct offering of 10.17mm common shares at $6 each (a 62% premium) to institutional investors.

STAT Plus: MannKind raises new cash to prop up a sinking inhaled insulin product

Motivated by a stock price that tripled over the past 10 days and in real need for new cash, MannKind (MNKD) sold 10 million shares in an overnight stock offering…

CombiMatrix Corporation Stockholders Approve Merger Agreement With Invitae Corporation

IRVINE, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) ("CombiMatrix" or the "Company"), a family health molecular diagnostics company specializing in DNA-based r...

CombiMatrix Corporation Reminds Shareholders to Vote "FOR" the Merger With Invitae Corporation

IRVINE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX) ("CombiMatrix" or the "Company"), a family health molecular diagnostics company specializing in DNA-based r...

MannKind Announces $61 Million Registered Direct Offering of Common Stock

WESTLAKE VILLAGE, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) and (TASE:MNKD) today announced that it entered into definitive agreements with certain institutional ...

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [174 Associated Companies listed on BioPortfolio]

MannKind Corporation

MannKind Corporation (Nasdaq:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its ...

Toshiba Corporation

Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...

MannKind

MannKind is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product c...

Bruker Daltonics

Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analy...

MannKind Corporation and Tolero Pharmaceuticals

Tolero is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat and cure cancer and other life-threatening diseases. Tolero has use...

More Information about "MannKind Corporation" on BioPortfolio

We have published hundreds of MannKind Corporation news stories on BioPortfolio along with dozens of MannKind Corporation Clinical Trials and PubMed Articles about MannKind Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MannKind Corporation Companies in our database. You can also find out about relevant MannKind Corporation Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Corporate Database Quicklinks



Searches Linking to this Company Record